Cadrenal Therapeutics (CVKD)

• Market cap: $17.4M
• 1 day: -2.61%
• 5 days: -2.36%
• 1 month: 7.96%
• 3 months: -41.99%
• 6 months: -31.37%
• Year to date: 1.77%
• 1 year: -59.76%
• 5 years: -87.93%
• 10 years: -87.93%
• Sector: Healthcare
• Industry: Biotechnology

About: Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.

Employees: 4